CTOs on the Move


 
Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.omicia.com
  • 1625 Clay Street 2nd Floor
    Oakland, CA USA 94612
  • Phone: 510.595.0800

Executives

Name Title Contact Details

Funding

Omicia raised $23M on 06/09/2016

Similar Companies

Ask Linda Pet Sitting

Ask Linda Pet Sitting is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Incept BioSystems

Incept BioSystems is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.

SeniorBridge Family

SeniorBridge Family is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.